

IBA & Proton Therapy

ITAPA - 15/03/23











What is Proton Therapy?




- Use of protons instead of photons to deliver a dose of radiation to a tumor
- The physics of proton therapy allow you to deliver the dose with minimal radiation exposure of healthy organs resulting in:
 - Improvement of local control through dose escalation
 - Reduction of side effects
 - Lower risk of induced disorders (e.g. secondary cancers or child growth abnormality);
 - More possibilities for re-irradiation

Photons vs Protons








Why does Proton therapy make sense now?

- Need for precision cancer care patients still exists TODAY
- Opportunity after COVID to provide better care and fight backlog
- More and more evidence being generated showing the benefit of proton therapy




Patients will still always face many challenges...


Growth & demand for proton therapy in Europe



Total number of patients treated in **Europe** according to PTCOG data








2020

Source: 2012 2014 2016 2018
PTCOG Statistics (2022) Years

Increasing clinical evidence for indication




- Majority in CNS, pediatric, prostate, breast, and lung
- Mainly focused on side-effects reduction

Source trial.gov

Committed today and tomorrow to proton therapy

100% committed to Proton Therapy



1986

IBA founded by Yves Jongen in Belgium




2001

First treatment at Mass General Hospital, Boston, USA



2014

World' first IMPT compact proton therapy system - Proteus®ONE




2020


100,000+ patients have been treated with IBA proton therapy systems


IBA PT Global Market Leader

Total number of patients treated by vendor (share %) (2019 PTCOG data)




IBA PT Global Market Leader






IBA proton therapy centers – Largest network & experience



Technology

- Compact systems are now system of choice (e.g. ProteusONE)
- Technology enabling increased patient throughput (300-350 patients a year)
- Future technologies under development will further increase throughput and increase quality
 - DynamicARC® (25+% more patients)
 - ConformalFLASH® (ultra hypofractionation)





Feasibility: what has changed?


- Smaller CAPEX / OPEX investment
- Small footprint & volume, less infrastructure

• Footprint: 330 m²

Volume: 1735 m³

- Consumption 650 MWh/year (13200 fractions)
- Maximum required power: 540 kVA
- IBA can deliver faster
 - Expanded manufacturing
 - Unmatched installation team size / expertise
 - Project management & building support
- ProteusONE's expandable systems design for future growth
 - Allows for smart center planning
 - Avoids future obsolescence technology mismatch

Proteus®ONE




17M€ investment for space of 10,000m²

- Lead time and cost reduction with higher quality output
- Waste reduction and material flows optimization
- Carbon neutral building
- Aligning capacity to demand-guaranteed on time delivery









Single ProteusONE - Typical Project Timeline

Clinical Building construction: 18-24 months ProteusONE installation: 12 months commissioning: 3 months **Building Readiness** ProteusONE system 1st patient Date (BRD) accepted treated ProteusONE system delivered on site



- 250-300 pacientov/ročne

 len malé % zo žiadostí o protónovú terapiu
- Náklady na zahraničnú protónovú terapiu ——Cca 7M ročne

Ekonomicko - prevádzkové hospodárenie protónového centra

- Úhrady za jednu frakciu cca 1200 EUR —— 15,8M EUR/ rok
- Prevádzkové náklady(servis, prevádzka budovy, energie, personál) ———4-5M EUR/ rok

Thank you



